Cancers of the upper aerodigestive tract (UADT) include malignant tumors of the oral cavity, pharynx, larynx, and esophagus and account for 6.4% of all new cancers in Europe. In the context of a multicenter case-control study conducted in 14 centers within 10 European countries and comprising 1,511 cases and 1,457 controls (ARCAGE study), 115 single nucleotide polymorphisms (SNP) from 62 a priori-selected genes were studied in relation to UADT cancer. We found 11 SNPs that were statistically associated with UADT cancers overall (5.75 expected). Considering the possibility of falsepositive results, we focused on SNPs in CYP2A6, MDM2, tumor necrosis factor (TNF), and gene amplified in squamous cell carcinoma 1 (GASC1), for which low P values for trend (P trend < 0.01) were observed in the main effects analyses of UADT cancer overall or by subsite. The rare variant of CYP2A6 À47A>C (rs28399433), a phase I metabolism gene, was associated with reduced UADT cancer risk (P trend = 0.01). Three SNPs in the MDM2 gene, involved in cell cycle control, were associated with UADT cancer. MDM2 IVS5+1285A>G (rs3730536) showed a strong codominant effect (P trend = 0.007). The rare variants of two SNPs in the TNF gene were associated with a decreased risk; for TNF IVS1+123G>A (rs1800610), the P trend was 0.007. Variants in two SNPs of GASC1 were found to be strongly associated with increased UADT cancer risk ( for both, P trend = 0.008). This study is the largest genetic epidemiologic study on UADT cancers in Europe. Our analysis points to potentially relevant genes in various pathways. [Cancer Res 2009;69(7):2956-65] 
Introduction
Cancers of the upper aerodigestive tract (UADT) include malignant tumors originating from the oral cavity, pharynx, larynx, and esophagus (1) . Altogether, UADT cancers account for 5.2% of all new cancer cases worldwide and 6.4% in Europe (2, 3) . Each year, there are more than 180,000 new cases and 105,000 deaths from cancer of the UADT in Europe; 32% of new cases occur in the oral cavity, 19% in the pharynx, 24% in the esophagus, and 25% in the larynx (2) . Within Europe, incidence rates vary considerably, with high rates being observed in France, Italy, Spain, and countries in Central Europe, particularly in Hungary (2) . This is thought to be mainly because of different patterns of alcohol and tobacco consumption and types of alcoholic beverage between European populations.
Established etiologic factors include tobacco consumption (both smoking and chewing) and heavy alcohol drinking (4, 5) . Tobacco and alcohol jointly account for 80% of UADT cancer (6) (7) (8) , but only a fraction of subjects exposed to these carcinogens will develop neoplastic lesions. Alcohol-and tobacco-related cancers are of special interest in molecular epidemiology because these exposures are thought to interact with a variety of genetic factors (9) . There are gene polymorphisms involved in the metabolism of carcinogens from tobacco and alcohol in DNA repair and cell cycle control that may contribute to interindividual variation of risk. The study of single nucleotide polymorphisms (SNP) in UADT cancer etiology may help to identify high-risk subgroups and to better understand the pathways leading to these cancers. A crucial point is the appropriate selection of candidate genes and functionally relevant polymorphisms.
Alcohol is metabolized to acetaldehyde by alcohol dehydrogenases (ADH), whereas subsequent conversion of acetaldehyde to acetic acid is catalyzed by aldehyde dehydrogenases (ALDH). The major part of alcohol and aldehyde metabolism is carried out in the liver, but metabolism by ADH, the cytochrome P450-related enzyme CYP2E1, and ALDH also occurs in the UADT. There is evidence that polymorphisms in the ADH1B, ADH1C, ADH7, and ALDH2 genes are associated with UADT cancers (10) (11) (12) .
Aromatic and heterocyclic amines, substances present in tobacco, require metabolic activation to interact with DNA. These major groups are metabolized by cytochrome P450-related enzymes, with CYP1A1, CYP1A2, CYP2A6, and CYP2D6 being some of the most studied polymorphic genes for these enzymes. Other polymorphisms related to tobacco metabolism may also be relevant to UADT cancer risk. After N-acetylation, the Nhydroxyaromatic and N-hydroxyheterocyclic amines are further activated by N-acetyltransferase to acetoxy intermediates, which react with DNA to form adducts. Two N-acetyltransferase genes, NAT1 and NAT2, are highly polymorphic. The NAT2 gene is involved in the development of bladder and colorectal cancer (13) . Another important group of phase II enzymes is the glutathione S-transferase family of genes, including GSTM, GSTT, and GSTP genes. For many of these genes, several studies on UADT cancers have been conducted in different populations, but results are very inconsistent (14) (15) (16) (17) (18) .
Other potentially important sources of interindividual variability in relation to the development of cancer are DNA repair capacity and cell cycle control. The association between different variants in these pathways and UADT cancer has been investigated in multiple studies, but the results are inconsistent (19) (20) (21) (22) (23) (24) (25) .
Here, we present a large study of >3,000 UADT cancer cases and controls recruited in 10 European countries that was conducted to investigate the association of genetic polymorphisms with the risk of these tumors. One of the major objectives of the study was to investigate the role of genetic variation with regard to the metabolism of alcohol and carcinogens from tobacco smoke, as well as DNA repair in the development of UADT cancers. We present the main effects of more than a hundred a priori-selected variants involved in various pathways, as well as some SNPs for which we have no prior knowledge of function. In addition, relevant stratified analyses investigating effect modification are presented.
Materials and Methods
Study population. ARCAGE (alcohol-related cancers and genetic susceptibility in Europe) is a multicenter case-control study conducted in 14 centers within 10 European countries: Prague (Czech Republic); Bremen (Germany); Athens (Greece); Aviano, Padova, and Turin (Italy); Dublin (Ireland); Oslo (Norway); Glasgow, Manchester, and Newcastle (United Kingdom); Barcelona (Spain); Zagreb (Croatia); and Paris (France). The IARC (Lyon, France) was responsible for the overall coordination of the study. The study has been described in more detail previously (26) .
Briefly, according to the same protocol, each center recruited a group of newly diagnosed cases of UADT cancers (within 1 year of diagnosis), including oral cavity, pharynx, larynx, and esophagus, and a comparable group of hospital-or population-based controls. The subjects were recruited between January 2002 and December 2005, except for the French center where subjects were enrolled between 1987 and 1992. All cases were histologically or cytologically confirmed. Controls were frequency matched by sex, age, center, ethnicity, and referral (or residence) area to the case group. Hospital controls were selected from a strictly defined list of admission diagnoses by diseases unrelated to alcohol, tobacco, or dietary practices. The proportion of controls within a specific diagnostic group did not exceed 33%. In United Kingdom centers, control subjects were selected by random sampling from the registered list of persons in the general practice with which the case was registered.
The study was approved by the IARC ethics committee as well as the local ethics committees, and each participant provided written informed consent. Non-Caucasians were excluded from analysis because there were only 13 of them and adjustment for ethnicity would have resulted in sparse cells. Both cases and controls underwent a face-to-face interview on current and previous alcohol consumption, dietary habits, tobacco consumption, and other lifestyle factors using the same questionnaire. Overall, the average participation rate was 82% among cases and 68% among controls. A total of 2,304 cases and 2,227 controls were included in ARCAGE, but DNA for genotyping was available for 1,788 cases and 1,685 controls. Of the remaining 1,058 subjects, 801 did not accept to give blood and DNA quality was not good enough for genotyping for 257.
Selection of relevant polymorphisms. A priori, we decided to include any SNP that satisfied at least one of the following criteria: (a) allele frequency >5% in Caucasians, (b) a previously reported association with lung or UADT cancer (P < 0.05), or (c) low or unknown allele frequency in Caucasians but high allele frequency in non-Caucasians (>25%). We selected SNPs following the third criteria due to the incompleteness of the SNP databases at the beginning of the study. We reasoned that if a diseaserelated SNP is common in non-Caucasian population, but information on its prevalence in the Caucasian population was limited, it was still of high enough priority to be included. An initial search was conducted at the start of the study in 2002 to identify all genes with some preliminary data of an association with UADT cancers or genes that may have an association based on their supposed biological function. The review was conducted using overviews of genetic susceptibility and cancer (27, 28) and gene expression analysis of UADT cancer (29) . In addition, a Medline search using keywords such as ''genetic, '' ''susceptibility, '' and ''cancer'' was performed. This review resulted in a list of 92 genes, which were considered to be the most likely candidates in tobacco-or alcohol-related cancer susceptibility.
Before genotyping, a review of the literature about polymorphisms of the relevant genes was carried out. The list of polymorphisms was expanded with information from more recent literature and publicly available databases (National Center for Biotechnology Information dbSNP, 24 HGVbase, 25 and SNP Consortium 26 ). Information recorded for each polymorphism included its exact position with respect to a reference Genbank sequence, its nature (SNP, insertion/deletion, repeat), its known functional effect (e.g., amino acid change), the allelic frequencies in various human ethnic groups, and the flanking sequence. The final result was 554 SNPs from 92 genes all relevant to UADT cancers and meeting our inclusion criteria.
In total, two to three common SNPs were selected per gene. SNPs in the coding regions of the genes were preferred to the noncoding SNPs, as well SNPs with some published evidence of functionality (30, 31) .
These selection criteria resulted in a final group of 166 SNPs from 76 genes to be included on the ARCAGE-ARRAY. This was a compromise between the suitable SNPs, candidate genes, and the possible volume of the genotyping.
Genotyping. Genotyping of all subjects, using an array-based methodology, was conducted by the arrayed primer extension (APEX) method (32, 33) . Microarray spotting and genotyping by APEX reactions were conducted as described (32) . Signal detection and interpretation were performed by Genorama imaging and analysis software (Asper Biotech Ltd. 27 ). Validation of ARCAGE-ARRAY. For the array validation, 125 (some of them in duplicate) anonymous human DNA samples from the SNP500 collection (so-called Coriell samples) were genotyped for the selected 166 polymorphisms. The samples included subjects from the main ethnic groups represented in the United States, with a subset of Centre d'Etude du Polymorphisme Humain families. The genotype data of SNP500 collection samples generated by bidirectional sequencing are publicly available on the Web site. 28 Markers that did not satisfy quality control criteria were replaced with neighboring markers.
Data analysis. There were 1,788 cases and 1,685 controls with DNA available. Subjects with a call rate below 90% for the 166 SNPs (that is <150 SNPs called) were excluded. This led to the inclusion of 3,044 subjects (cases and controls) in the analysis. Some 10% of the studied subjects were randomly selected and their DNA samples were reanalyzed for each polymorphism to evaluate the concordance of the genotyping. SNPs with less than 95% concordance and 95% call rates were excluded from the analysis. This led to the exclusion of 39 SNPs.
Departure from Hardy-Weinberg equilibrium (HWE) in the controls was tested by a m 2 test using a type I error probability of a = 0.01. We excluded SNPs with P < 0.01 (rather than P < 0.05) because of the anticonservatism of this test, as noted by Wigginton and colleagues (34) . This resulted in the exclusion of a further 12 SNPs, leaving 115 SNPs for data analysis.
Demographic variables and factors associated with UADT cancer, including center, sex, age at diagnosis (in 5-y groups), smoking, and alcohol habits, were included in the analysis. With respect to smoking, subjects were classified as never, former, or current smokers. Cumulative tobacco consumption was calculated as pack-years (i.e., the product of smoking duration in years and intensity in packs per day). With respect to alcohol drinking, subjects were classified as never drinkers and drinkers of <1, 1 to 2, 3 to 4, and z5 drink equivalents per day. The definition for one drink equivalent was 14 g ethanol, which approximately corresponds to 150 mL wine, 330 mL beer, and 36 mL spirits (5) . Drinks per day were calculated by summing each type of alcohol in drink-years and dividing this by the total duration of alcohol drinking. Seventy-six subjects with missing information on at least one of the matching and adjustment variables were excluded from the analyses [i.e., age (7 missing), sex (1 missing), smoking habit 
, where L is the number of SNPs. Deviations from the line of equality (y = x) correspond to SNPs that deviate from the null hypothesis of no association at any locus.
Analyses were stratified by country, smoking status (never, former, and current), alcohol intake (none or light drinkers of <1 drink per day, moderate drinkers of 1 to <3 drinks per day, and heavy drinkers of 3+ drinks per day), and subsite (oral cavity/oropharynx, larynx/hypopharynx, and esophagus).
Forest plots were used to present the stratified results (allele ORs) for the SNPs with a P value for trend of <0.01 overall or by subsite.
Heterogeneity among the stratified ORs was assessed by conducting a likelihood ratio test comparing a model that included the product terms between the genetic variant and the stratification variable and a model without a product term. As ORs for different subsites were not mutually independent because the controls overlap, the Q test for heterogeneity was calculated instead of m 2 . All tests were two sided, and a P value of <0.05 was considered to be statistically significant. The statistical analyses were conducted with Statistical Analysis System software (version 9.1; SAS Institute). Linkage disequilibrium between variants was tested in the controls by measure of R 2 using STATA software (version 8). The false-positive report probability (FPRP) for statistically significant observations was estimated using the procedure recommended by Wacholder and colleagues (35) . Table 1 shows the demographic characteristics of the 1,511 cases and 1,457 controls included in the analyses. The age distribution was comparable between cases and controls, whereas more males were recruited among cases. The average number of subjects recruited by each center was 108 for the cases and 104 for the controls. As expected, the proportion of current smokers was higher among cases than among controls, as well as the average number of drinks per day (3.2 drinks in cases; 1.7 drinks in controls). Figure 1 presents the comparison between the observed and expected distribution of the trend test statistic (m 2 ) adjusted for possible confounders. We observed 11 SNPs with P values for trend test (P trend) of <0.05 against 5.75 expected under the null hypothesis of no association at any locus. By subsite, 10 SNPs with statistically significant P trend were found for esophageal cancer, 8 for oral cavity/oropharynx, and 4 for larynx/hypopharynx cancer.
Results
Results on the main effects for the 115 SNPs are presented in Tables 2 to 4 , grouped by presumed gene function.
Among phase I metabolizing genes (Table 2) , we found two SNPs associated with the risk for UADT cancer. The rare variant allele of CYP2A6 À47A>C (rs28399433) was associated with a reduced risk for UADT cancer (P trend = 0.01), whereas the rare variant allele of CYP2C8 intron 9 G>A (rs1934951) was found to be associated with an increased risk of UADT (P trend = 0.02). We did not find any significant associations among SNPs in phase II metabolizing genes and genes coding for ADH and ALDH enzymes shown in Table 2 .
Among the DNA repair genes ( Table 3 ). For two SNPs involved in the base excision repair gene, XRCC1 P206P (rs915927) and XRCC3 IVS5-571A>G (rs861530), the corresponding rare alleles were associated with reduced UADT cancer risk (P trend = 0.04 for both).
We found four significant associations between SNPs involved in cell cycle control and UADT cancers risk ( Table 4 ). The CDKN1A A>G (rs2395655) variant was associated with an increased risk of UADT particularly for the homozygous variant (OR, 1.26; 95% CI, 0.99-1.59; P trend = 0.045). Three SNPs in the MDM2 gene were associated with UADT cancer risk. In particular, the rare allele of MDM2 IVS5+1285A>G (rs3730536) showed a strong codominant effect (P trend = 0.007). The three MDM2 variants were in linkage disequilibrium among the controls (R 2 range: 0.36-0.95). As shown in Table 4 , the rare alleles of two SNPs in the tumor necrosis factor (TNF) gene, particularly the TNF IVS1+123G>A (rs1800610) variant (P trend = 0.007), were associated with a decreased UADT cancer risk. These two SNPs were in weak linkage equilibrium (R 2 = 0.05). The two variants of gene amplified in squamous cell carcinoma 1 (GASC1) gene were found to be strongly associated with increased risk of UADT cancer (P trend = 0.008 for both the SNPs; R 2 = 0.97; Table 4 ). Additionally, the LZTS1 G>A (rs3735836) heterozygous variant was associated with increased UADT cancer risk (OR, 1.40; 95% CI, 0.99-1.97; P trend = 0.036); two cases but no controls were homozygous for the rare variant. With respect to esophageal cancer (data not shown in Table 4 ), variant alleles of deleted in esophageal cancer 1 (DEC1) and deleted in lung and esophageal cancer 1 (DLEC1) genes were associated with a decreased risk of this cancer [DEC1 5jUTR G>A (rs3750505): heterozygotes OR, 0.50; 95% CI, 0.29-0.85; P trend = 0.06; DLEC1 UTR C>T (rs2073401): P trend = 0.03]. Figure 2 shows stratified results for the four SNPs for which we found strong significant associations with UADT cancer risk (P trend < 0.01, overall or by subsite): CYP2A6 À47A>C, MDM2 IVS5+1285A>G, TNF IVS1+123G>A, and GASC1 intron 10 G>T. Only one SNP is presented for the GASC1 gene because the two variants were in strong linkage disequilibrium.
As shown in Fig. 2 , for CYP2A6 À47A>C (rs28399433), we observed a strong association of the variant allele with esophageal cancer (OR, 0.32; 95% CI, 0.16-0.64; P = 0.001) and less strong associations with cancer of the oral cavity/oropharynx (OR, 0.76; 95% CI, 0.58-1.01; P = 0.057) and larynx/hypopharynx (OR, 0.88; 95% CI, 0.65-1.19; P = 0.41), with a significant test for heterogeneity between the ORs by subsites (Q = 7.01; P = 0.03). The inverse association of the A allele with UADT cancer was highly significant among heavy drinkers (OR, 0.47; 95% CI, 0.31-0.71), with a significant test for heterogeneity (m 2 = 8.91; P = 0.01). We did not observe significant heterogeneity in the stratified results with respect to the MDM2 variant.
We observed a considerably stronger association of TNF IVS1+123G>A (rs1800610; OR, 0.67; 95% CI, 0.50-0.89) with UADT cancer among heavy drinkers than among moderate drinkers, but the m 2 for heterogeneity was not significant (P = 0.11). We found a stronger positive association of the variant rare allele of GASC1 intron 10 G>T (rs818912) with the risk of esophageal cancer (OR, 1.42; 95% CI, 1.07-1.87; P = 0.011) than with risk of oral cavity/oropharyngeal cancer (OR, 1.21; 95% CI, 1.02-1.41; P = 0.04) or laryngeal/hypopharyngeal cancer (OR, 1.07; 95% CI, 0.89-1.28; P = 0.53).
The associations of CYP2A6 À47A>C, MDM2 IVS5+1285A>G, TNF IVS1+123G>A, and GASC1 intron 10 G>T with UADT cancer were likely to be true positives (FPRP V 0.2) when the prior probability was at least 10% (FPRP: 0.125, 0.060, 0.061, and 0.067, respectively) but not with a prior probability of 1% (FPRP: 0.611, 0.412, 0.419, and 0.441, respectively; ref. 35 ).
Discussion
We studied 115 SNPs involved in various pathways in relation to UADT cancer in 1,511 cases and 1,457 controls recruited in 10 European countries.
Eleven SNPs were associated with UADT cancers, whereas 5 or 6 were expected. More statistically significant associations were found for esophageal cancer risk than for oral cavity/oropharynx and larynx/hypopharynx, but the possibility of false-positive findings because of the small number of esophageal cases should be taken into account. Considering the possibility of false-positive results, our stratified analysis focused on four SNPs in CYP2A6, MDM2, TNF, and GASC1, for which low P values for trend (P trend < 0.01) were observed in the main effects analyses overall or by subsites. The CYP2A6 gene is responsible for the metabolic activation of N-nitrosamines (36) . A recent review by Kamataki and colleagues (37) suggested that genetic polymorphisms of CYP2A6 may affect cancer risk in smokers but not in nonsmokers.
In our data, we found evidence of a stronger effect in heavy drinkers (P = 0.01). No interaction by smoking status was evident. Tan and colleagues (38) showed that the CYP2A6 gene deletion is associated with an increased risk of lung and esophageal cancer but not with a reduced tendency to smoke. The CYP2A6*4 deletion is, however, rare in European populations, with a prevalence of between 0% and 5% (39, 40) , and will have a minimal effect on the association with other more common CYP2A6 variants. The apparent inverse association of CYP2A6 À47A>C was also more evident for esophageal cancer compared with the other sites. A recent study (41) on lung cancer found a similar inverse association of the rare variant of the À47A>C polymorphism, irrespective of smoking status. Even in the absence of information on the CYP2A6 gene deletion, our results still support a role for this SNP.
MDM2 is a target gene of the transcription factor tumor protein p53. Overexpression of this gene can inactivate the protein p53, diminishing its tumor suppressor function. We have found different MDM2 polymorphisms to be associated with either increased or decreased UADT cancer risk. The rs1695146 and rs2701092 SNPs are in strong linkage disequilibrium (R 2 = 0.95) but less so with rs3730536 SNP, the rare variant of which showed the strongest inverse association. No association with UADT cancer risk was found for P53 gene.
To our knowledge, there has been only one published report on MDM2 polymorphisms and UADT cancer risk (25) . The authors reported that the rare variants of both the P53 72Arg>Pro and the MDM2 309T>G polymorphisms were associated with an increased risk of esophageal cancer with an apparent multiplicative interaction between the two SNPs. Pine and colleagues (42) reported that the rare variant of the MDM2 SNP at position 309 was not strongly associated with lung cancer risk, whereas Li and colleagues (43) found that the same variant was associated with decreased risk of lung cancer.
We found apparent inverse associations for two polymorphisms in the TNF gene, a proinflammatory cytokine with both procarcinogenic and anticarcinogenic proprieties (44) . A recent study (45) on the association between TNF and breast cancer risk concluded that the TNF IVS1+123G>A rs1800610 SNP was not significantly associated with breast cancer. To the best of our knowledge, there have been no published reports on TNF IVS1+123G>A rs1800610, TNF À1210C>T rs1799964, and UADT cancer risk.
Two variants of the GASC1 gene were found to be strongly associated with increased risk of UADT cancer, particularly esophageal cancer. GASC1 is located at 9p24, a region frequently amplified in tumor tissues of esophageal squamous cell carcinomas (46) . Yang and colleagues cloned GASC1 and showed that GASC1 was overexpressed in cell lines. Using several independent lines of evidence, Cloos and colleagues (47) have shown that GASC1 and its homologues JMJD2A and JMJD2B demethylate the repressive histone H3K9me3/me2 marks both in vitro and in vivo. These findings indicate that histone trimethylation is a reversible modification and may potentially have far-reaching implications for human disease, particularly cancer. Only one association study has been published on GASC1 variants and cancer risk, notably a genome-wide case-control study of esophageal cancer using GeneChip Mapping 10K array (48) . In that study, the rs1340513 SNP in the GASC1 gene was found to be associated with esophageal cancer risk. Based on HAPMAP data, there is a strong association between this variant and rs818912 in Europeans (R 2 = 0.96). In addition to the four SNPs described above, there was evidence of an association (0.01 < P < 0.05 with main effects considering both a dominant and a codominant model) of CYP2C8 intron 9 G>A rs1934951, ERCC1 IVS5+33A>C rs3212961, ERCC4 S835S rs1799801, XRCC1 P206P rs915927, XRCC3 IVS5-571A>G rs861530, CDKN1A A>G rs2395655, DLEC1 UTR C>T rs2073401, and LZTS1 G>A rs3735836 with UADT cancer risk. Replication of these associations in other large studies is warranted.
Three of nine ADH and ALDH SNPs were excluded from the analyses due to deviation from HWE or low call rates, particularly ADH1B H48R (rs1229984), for which a recent study of about 3,800 cases and 5,200 controls found results that were strongly significant (12) .
Use of hospital controls, in all but the United Kingdom centers, would have been considered a limitation for traditional casecontrol studies. However, only controls with admission diagnoses unrelated to diet, alcohol, or smoking were eligible to participate. Furthermore, the main disadvantage of the case-control studies, that is, susceptibility to bias when estimating effects of exposures that are measured retrospectively, does not generally apply when studying genetic effects and statistical interaction between genotype and environmental exposures (49) . In any case, the genetic associations were generally similar for the United Kingdom and the other centers, as well as allele frequencies. Population stratification is unlikely to have affected our results, given that we excluded from the analysis people who were not of European ethnicity, and allele frequencies did not differ substantially between countries. Genome-wide data from tobacco-related cancers within Europe that adjust for genetic markers of ethnicity show only limited evidence of genetic mixture within countries and little potential for population stratification (50) . Genome-wide data for the ARCAGE study have recently become available as part of a large initiative on f70% of participants using the Illumina 317K panel. Adjustment by genetic markers of ethnicity shows little or no change to results adjusted by country (data not shown).
Strengths of our study include the use of a standard protocol, the implementation of strict criteria for control selection, the use of a single laboratory for all DNA extraction, and the use of state-of-theart procedures for genetic determination, as well as detailed assessment of lifetime tobacco and alcohol consumption. We also included a large number of cases and controls, allowing for more statistical power in main effect and stratified analyses (26) .
This study is the largest genetic epidemiologic study on UADT cancers with biological samples available in Europe. Our analysis points to associations with genes in various pathways. Further detailed characterization of these pathways and replication in other large studies of head and neck cancer will be essential.
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